These novel findings were published in 2005 and suggested that dysregulation of IL-1 production is central to the pathogenesis of disease, and that IL-1 blockade might be beneficial in our patients with sJIA[66] (See Figure 2 for key publications on the role of IL-1 in sJIA). The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.